Mental DailyMental Daily
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Aa
Mental Daily
Aa
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • Opinion
Search
  • Clinical
  • Health
  • I/O
  • Cybernetic
  • Social
  • More
    • Opinion
    • My Bookmarks
Follow US
  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store
© 2022 - Mental Daily. All Rights Reserved.
Clinical

Experimental drug treatment tofersen may be useful for treating inherited form of ALS

Staff Writer
Staff Writer 3 years ago
Updated 2021/10/23 at 2:32 PM
Share
SHARE

A study in the New England Journal of Medicine highlights the results of phase 1/2 clinical trial involving the experimental drug treatment tofersen, also known as BIIB067.

According to researchers at the Washington University School of Medicine, tofersen may be effective at reducing the severity of the inherited form of amyotrophic lateral sclerosis (ALS). The progressive neurodegenerative disease is caused by a mutation in the gene SOD1.

“Tofersen is an antisense oligonucleotide that mediates the degradation of superoxide dismutase 1 (SOD1) messenger RNA to reduce SOD1 protein synthesis. Intrathecal administration of tofersen is being studied for the treatment of amyotrophic lateral sclerosis (ALS) due to SOD1 mutations,” the findings read.

In the study, 50 participants received doses of either tofersen or placebo, administered for 12 weeks.

“A total of 50 participants underwent randomization and were included in the analyses; 48 participants received all five planned doses. Lumbar puncture–related adverse events were observed in most participants,” the co-authors stated in the findings.

“In adults with ALS due to SOD1 mutations, CSF SOD1 concentrations decreased at the highest concentration of tofersen administered intrathecally over a period of 12 weeks. CSF pleocytosis occurred in some participants receiving tofersen. Lumbar puncture–related adverse events were observed in most participants.”

The findings provide a glimpse of what is a potential drug treatment efficient at combating the effects of ALS, however, more research is needed.

Photo: kirstypargeter

You Might Also Like

Dementia risk factors differ by ethnicity, according to new research

Researchers investigate how endocannabinoids regulate the brain’s stress response

Study shows the risk of eating disorders may be lower among vegans

Study boasts MDMA-assisted therapy for PTSD patients

How the brain is organized is revealed by the largest genetic study of brain structure to date

TAGGED: tofersen, ALS, amyotrophic lateral sclerosis
Staff Writer July 8, 2020
Share this Article
Facebook Twitter Whatsapp Whatsapp Email Print
Previous Article A US-based study shows the state of gender bias and equal rights
Next Article Older adults with dual sensory impairment at a higher risk of dementia

Recommended

Clinical

Dementia risk factors differ by ethnicity, according to new research

2 Min Read
Clinical

Researchers investigate how endocannabinoids regulate the brain’s stress response

2 Min Read
Clinical

Study shows the risk of eating disorders may be lower among vegans

2 Min Read
Clinical

Study boasts MDMA-assisted therapy for PTSD patients

1 Min Read
//

We are a trusted online source for research news and resources on all aspects of the mind and human behavior.

Verticals

  • Clinical
  • Health
  • Social
  • I/O
  • Opinion

Social

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Links

  • About
  • Contact
  • The Editor
  • Terms & Conditions
  • Privacy Policy
Follow US

© 2022 Mental Daily. All Rights Reserved.

  • Twitter
  • Facebook
  • Instagram
  • Inc. Profile
  • Google Play Store

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?